Genelux doses first subject in Phase II trial of NSCLC treatment
Genelux has dosed the first subject in the Phase II VIRO-25 clinical trial in the US, designed to assess the…
Oncology
-
-
Zymeworks doses first subject in Phase I trial of ZW171 for various forms of cancer
Canadian biotechnology company Zymeworks has dosed the first subject in a Phase I trial of ZW171 to treat advanced or…
-
FDA clamps partial hold on Phase III trial of BioNTech & OncoC4’s NSCLC therapy
The US Food and Drug Administration (FDA) has placed a partial clinical hold on the registrational Phase III PRESERVE-003 trial…
-
Nurix Therapeutics’ NX-5948 shows promise in Waldenstrom’s macroglobulinaemia trial
US-based biopharmaceutical company Nurix Therapeutics has reported positive clinical data from its ongoing Phase Ia/Ib trial of NX-5948, a BTK…
-
Anixa Biosciences administers second CAR-T dose in ovarian cancer trial
Anixa Biosciences has administered the second dose of its chimeric antigen receptor T-cell (CAR-T) therapy to a patient in a…
-
Exelixis and MSD to trial cancer therapies together in clinical collaboration
US-based biotechnology companies Exelixis and MSD have partnered to assess the potential of combining their respective cancer therapies in upcoming…
-
Oncoinvent doses first subject in Phase II ovarian cancer treatment trial
Oncoinvent has dosed the first subject in the Phase II clinical trial of Radspherin, an alpha-radiation therapy, for the treatment…
-
Pfizer reports positive data from prostate cancer combination therapy trial
Pfizer has announced positive topline data from the Phase III TALAPRO-2 study of TALZENNA (talazoparib) plus XTANDI (enzalutamide) in patients…
-
KaliVir doses first subject in Phase I/Ib solid tumour treatment trial
KaliVir Immunotherapeutics has dosed the first subject in a Phase I/Ib clinical trial for its new oncolytic immunotherapy, VET3-TGI, designed…
-
MSD’s Phase III trial of head and neck cancer treatment meets primary endpoint
MSD (Merck & Co.) has reported that the Phase III KEYNOTE-689 trial of its KEYTRUDA (pembrolizumab) for the treatment of…
